Pharmafile Logo
Pharmafocus logo
Advanced Search

Sales and Marketing

Showing 15 posts of 11527 posts found.

Boehringer Ingelheim says Phase III trials for its Ofev slowed progression of fatal lung disease

June 27, 2016 Research and Development, Sales and Marketing Boehringer Ingelheim, drug trial, idiopathic pulmonary fibrosis, research

German drugmaker Boehringer Ingelheim said late-stage trials for its Ofev (nintedanib) to treat a fatal lung condition slowed progression of …
News

Sanofi, Boehringer Ingelheim sign definitive agreements for swap

June 27, 2016 Research and Development, Sales and Marketing Boehringer Ingelheim, Financial, Sanofi, business swap, merger and acquisition

French drugmaker Sanofi (Euronext: SAN) and German pharma firm Boehringer Ingelheim have signed a definitive agreement for a business swap announced …
News

Weekly Movers: Lpath, Paratek, Inovio…

June 27, 2016 Research and Development, Sales and Marketing

Shares in Lpath (Nasdaq: LPTN) jumped 55% after the company said it has secured a two-year $1.45 million grant by …
Feature

Brexit may also create opportunities for UK’s pharmaceutical and medical device industries – report

June 27, 2016 Research and Development, Sales and Marketing

Even though UK’s exit from the European Union undoubtedly creates significant issues for the UK pharmaceutical and medical device industries …
News

Astellas UK suspended from ABPI for “deception” and other cultural failings

June 24, 2016 Medical Communications, Research and Development, Sales and Marketing ABPI, Astellas, cultural failings

Astellas UK has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for a period …
News

“Immediate challenges” for UK pharma post-Brexit, says ABPI

June 24, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, brexit

The UK life sciences industry has expressed dismay at the result of the EU referendum, but has pledged to work …
News

FDA approves expanded label for Allergan’s Avycaz

June 24, 2016 Medical Communications, Research and Development, Sales and Marketing Allergan, Avycaz, FDA, expanded label

Allergan (NYSE: FDA) has announced that the US Food and Drug Administration (FDA) has approved its supplemental new drug application …
News

Genmab’s CLL drug gets negative opinion from EMA committee

June 24, 2016 Medical Communications, Research and Development, Sales and Marketing Arzerra, CHMP, CLL, EMA, Genmab, blood cancer

Genmab A/S (Nasdaq Copenhagen: GEN) said its drug Arzerra (ofatumumab) received a negative opinion by the Committee for Medicinal Products …
News

Sanofi to add future payments onto Medivation offer, according to reports

June 23, 2016 Research and Development, Sales and Marketing Medivation, Sanofi

Sanofi (NYSE: SNY) is considering adding future payments, tied to certain targets, to its proposed $9.3 billion takeover of US …
News

EU referendum outcome will have major consequences for UK’s pharma sector – GlobalData

June 23, 2016 Medical Communications, Sales and Marketing EMA, GlobalData, Pharma sector, brexit, referendum

The outcome of today’s referendum on the UK’s continuing membership of the European Union (EU) will have major consequences for …
News

AstraZeneca set to lose out on $80 million after US turns down flu vaccine

June 23, 2016 Sales and Marketing AstraZeneca, CDC, flu, flu vaccine

AstraZeneca has confirmed that its influenza vaccine, FluMist Quadrivalent, will not be used in the US during the 2016-17 flu …
News

Timely use of Novartis’ Entresto could prevent/delay over 28,000 US deaths a year – study

June 23, 2016 Research and Development, Sales and Marketing Entresto, JAMA Cardiology, Novartis, drug trial, research

A timely switch to Novartis’ (VTX: NOVN) heart failure drug Entresto (sacubitril/valsartan) in patients could prevent or delay more than …
News

Immunomedics’ chief financial officer resigns, shares fall

June 22, 2016 Research and Development, Sales and Marketing Immunomedics, Shares, cfo, stock market

Shares in Immunomedics (Nasdaq: IMMU) fell as much as 11% after the company said its chief financial officer Peter Pfreundschuh …
News

Nice backs two cancer drugs from Novartis

June 22, 2016 Research and Development, Sales and Marketing AbbVie, Amgen, Humira, NICE, Novartis, Sanofi, lung cancer, skin cancer

The National Institute for Health and Care Excellence (Nice) has backed two drugs form Novartis (VTX: NOVN) for lung cancer …
News

Impax to acquire Teva, Allergan generic drugs for $586 million

June 22, 2016 Research and Development, Sales and Marketing Allergan, Impax, Teva, generics

Impax Laboratories (NASDAQ: IPXL) has announced that it has entered into agreements with Teva and affiliates of Allergan to acquire …
News
The Gateway to Local Adoption Series

Latest content

Major funding opportunity opens for early cancer diagnostics

September 4, 2026

Androlabs receives UK authorisation for new Testavan presentation

September 4, 2026

CEPI backs African-led Bundibugyo Ebola vaccine development

September 3, 2026

Cytomos appoints life sciences executive to board

September 2, 2026

Cell therapy partnership aims to bring liver disease treatment closer to US patients

September 1, 2026